# The Enhanced Games Aren't About Sports. They're About Peptides.
> A doping-allowed Olympics is listing on the NYSE at $1.2B. We traced the money to the GLP-1 franchise that made Eli Lilly the first trillion-dollar drugmaker.
- Author: Barebone Research, Barebone AI
- Published: 2026-05-04
- Canonical: https://barebone.ai/resources/enhanced-games-peptide-boom-investment-thesis
- Publisher: Barebone AI (https://barebone.ai)
---
## The Spectacle
In three weeks, a 2,500-seat arena at Resorts World Las Vegas will host the first event in modern history where athletes are paid to dope on camera. The Enhanced Games — swimming, track, weightlifting, no anti-doping testing — puts up a **$25 million** purse: $250,000 for a win, and a **$1 million** bonus for anyone who beats a world record while medically supervised on performance-enhancing drugs.
This week, the company behind it lists on the New York Stock Exchange under the ticker ENHA, at a roughly **$1.2 billion** valuation, via a merger with a blank-check shell called A Paradise Acquisition Corp.
The spectacle is the marketing. The business is something else.
We used Barebone AI to do what would normally take an analyst a few days: pull the funding history, the SEC filings, the drugmakers' latest results, and the public-health data, and separate what the headline gets right from what it leaves out. The short version: the Enhanced Games are a billboard for a drug class that has already rewired the most valuable corner of pharma. **Eli Lilly's revenue went from $28 billion to $65 billion in four years. One in eight American adults is on the underlying drug.** Here are the receipts — and the parts the billboard doesn't show.
## What a Peptide Actually Is
Start with the molecule, because the whole thesis rides on it.
A peptide is a short chain of amino acids — the same building blocks as protein, just a handful of them strung together. Your body already runs on them; they are chemical instructions that tell cells what to do. Scientists learned to manufacture them, which means you can now buy an instruction: *lower blood sugar*, *suppress appetite*, *grow tissue*.
The famous one is semaglutide — sold as Ozempic for diabetes and Wegovy for weight loss. It is a GLP-1 peptide: it mimics a gut hormone that tells your brain you are full. That single mechanism is the engine under everything here.
And the adoption curve is not a niche. In a KFF national poll fielded in late 2025, **12% of US adults — about one in eight — said they were currently taking a GLP-1 drug**, with 18% having tried one at some point. Eighteen months earlier, the "currently taking" figure was 6%. It doubled.
That is the real market the Enhanced Games are riding on the back of — not the 30-odd athletes in Vegas, but the roughly 30 million Americans already injecting a peptide every week.
## The Category That Built a Trillion-Dollar Drugmaker
In November 2025, Eli Lilly became the first pharmaceutical company in history to cross a **$1 trillion** market value. (By early May it had eased back to roughly $870 billion as the stock cooled — still worth more than any other healthcare company on earth, and more than Visa.) The thing that got it there was almost entirely one product category: the GLP-1 peptides Mounjaro and Zepbound.
Look at the revenue line. For most of the last decade Lilly was a steady, unremarkable drugmaker. Then the incretin drugs landed.
| Year | Revenue | Growth |
|------|---------|--------|
| 2021 | $28.3B | — |
| 2022 | $28.5B | +1% |
| 2023 | $34.1B | +20% |
| 2024 | $45.0B | +32% |
| 2025 | $65.2B | +45% |
| 2026 (guidance) | $82–85B | ~+28% |
In the first quarter of 2026 alone, Lilly booked **$19.8 billion** in revenue, up 56% year over year. Mounjaro sales rose 125% to **$8.7 billion** in a single quarter; US Zepbound rose 79% to $4.1 billion. The company's two incretin drugs now generate more than half its total revenue.
Demand is the constraint, not appetite for the product. To build supply, Lilly has committed **more than $50 billion to US manufacturing since 2020**, including four new plants announced in February 2025 — among the largest domestic pharmaceutical build-outs of the past decade.
This is where the script most of you have seen needs a correction. A widely shared version of this story says "Novo Nordisk quietly paid $16.5 billion to lock down a single supplier two months ago." The deal is real but the details are off. It was **Novo Holdings** — the foundation that controls Novo Nordisk, not the drugmaker itself — that bought the contract manufacturer **Catalent** for $16.5 billion. It was announced in February 2024 and closed in December 2024, not this spring. As part of it, Novo Nordisk took over three fill-finish sites — the plants that actually fill the injection pens — for $11 billion. The motive in the headline is right: the bottleneck in this industry is making the stuff, not selling it. The date and the buyer are not.
## The Enhanced Games Are the Billboard
So where do the Enhanced Games fit? Not as a sports league. As a consumer funnel for that same peptide demand.
The company was founded by Aron D'Souza, an Australian lawyer-financier, and chaired by Christian Angermayer of Apeiron Investment Group. Its early backers read like a Silicon Valley contrarian roster: a January 2024 seed round drew **Peter Thiel**, Balaji Srinivasan, and Angermayer; a February 2025 Series B of roughly **$300 million** was co-led by 1789 Capital, the firm tied to Donald Trump Jr. Thiel is one early investor among several — not, as the louder version of this story claims, the man personally writing a $1.2 billion check. That $1.2 billion is the valuation the SPAC put on the whole company.
Read the company's own listing materials and the pivot is explicit. Enhanced calls itself a "performance products company," and its CEO talks about making "performance enhancements… available to consumers looking to optimize their own health and wellness." The Vegas event is a broadcast. The intended business is a direct-to-consumer and telehealth line selling the same molecules — sold under the banner of longevity and optimization rather than medicine.
That is the trade the spectacle is advertising: not "bet on a swim meet," but "the appetite for self-administered biology is large enough that a doping league is a viable customer-acquisition channel."
## The Record That Wasn't
Before anyone treats the athletic results as proof of the science, look at the swim everyone cites.
At a February 2025 trial in North Carolina, Greek sprinter Kristian Gkolomeev clocked **20.89 seconds** in the 50-meter freestyle — 0.02 faster than César Cielo's long-standing mark. The retelling is "world record, two weeks on peptides." Three things complicate it. He was wearing a full-length polyurethane "super-suit," the kind World Aquatics banned in 2010 precisely because it distorts records. The swim is recognized by no governing body. And in textile shorts that April, his time slowed to 21.03.
Then the cleaner data point arrived. In March 2026 — weeks before the Games — Australia's **Cameron McEvoy swam 20.88 in a standard suit, drug-tested, at a sanctioned meet**, breaking the actual world record without any of it. A tested athlete beat the "enhanced" time. The pharmacology may do plenty; the marquee evidence for it is shakier than the hook suggests.
## The Honest Caveat
This is the section the spectacle skips, and it is the one that matters.
**The science establishment is unanimously against it.** The World Anti-Doping Agency calls the Games "very dangerous"; USADA's chief has called the concept "a dangerous clown show, not real sport"; and in June 2025 World Aquatics moved to ban anyone involved from its events. These are not neutral observers, but they are the people who run the sports being imitated.
**The consumer side is a gray market with a regulatory tailwind that cuts both ways.** Beyond the FDA-approved GLP-1s, the "longevity" peptides in this story — BPC-157 for healing, CJC-1295 for anti-aging, others — largely are not approved drugs. The FDA placed 19 of them in a restricted compounding category in 2023 over safety and impurity concerns. In early 2026 the new HHS leadership began reversing that: BPC-157 was pulled off the restricted list in April 2026, and a federal advisory committee is scheduled to review it formally in July. That loosens access — and it means much of the demand still flows through vendors selling vials labeled "for research use only," with no dosing standards and no oversight. We are not doctors, and nothing here is an endorsement of injecting any of it.
**The category is real, but picking the winner is not automatic.** The cleanest evidence is the other GLP-1 leader. Novo Nordisk invented this market, and in February 2026 it guided to a **5% to 13% sales decline** for the year as US pricing fell and cheaper competition arrived. Same drug class, same year, opposite direction from Lilly.
| Company | 2025 sales growth | 2026 guidance |
|---------|-------------------|---------------|
| Eli Lilly | +45% | ~+28% |
| Novo Nordisk | +10% | −5% to −13% |
**And ENHA itself is a speculative microcap.** It is a freshly de-SPAC'd company with minimal revenue, an unproven consumer business, and a valuation built on a story. SPAC listings of pre-revenue narratives have a long history of disappointing the retail investors who arrive after the headline.
## What This Means
Strip away the Vegas lighting and a simpler picture is left. A class of manufactured biological instructions has gone from laboratory curiosity to a product one in eight adults uses, and it has reordered the most valuable part of the drug industry around itself. The Enhanced Games are a loud, deliberately provocative way of announcing that the appetite for self-administered enhancement now extends well past medicine into optimization and sport.
The durable signals are not in the arena. They are in who can actually manufacture peptides at scale — the constraint Lilly is spending $50 billion to relieve and Novo paid $16.5 billion to secure. They are in whether the FDA's compounding committee widens or narrows the legal path this summer. And they are in whether a category that minted a trillion-dollar company can survive its first real bout of price competition, which Novo's guidance says has already started.
The headline wants you to watch the swimmers. The question worth asking is who owns the supply, the approval, and the pricing power behind the needle — and whether you understand that before the next billboard goes up.
---
*Data: Barebone | Sources: Enhanced Group / A Paradise Acquisition Corp (NYSE listing release, SEC filings); Eli Lilly Q4 2025 and Q1 2026 results; Novo Nordisk FY2025 report; KFF Health Tracking Polls (May 2024, Nov 2025); FDA bulk drug substances compounding list; World Aquatics | Data as of May 4, 2026*